Jeremiah Deneve, DO, FACS
Dr. Jeremiah “Jig” Deneve is a surgical oncologist at UNC Health and the Lineberger Comprehensive Cancer Center. He specializes in complex surgery for peritoneal surface malignancies, Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy, Colorectal Cancer, Appendiceal Cancer, and Melanoma. He is an Associate Professor in the Division of Surgical Oncology at the UNC School of Medicine and Program Director of the school’s Surgical Oncology Fellowship.[1]
Education and Career
Dr. Deneve began his education by earning a Bachelor of Science degree at Auburn University at Montgomery. From there, he went on to earn his Doctor of Osteopathic Medicine degree at the Chicago College of Osteopathic Medicine of Midwestern University.
He completed his internship and residency at Emory University School of Medicine and fellowships in both Surgical Oncology at Moffitt Cancer Center at the University of South Florida and a Cardiothoracic Research Fellowship at Emory University School of Medicine.[1]
Before assuming his role at UNC Lineberger Comprehensive Cancer Center, Dr. Deneve practiced at the University of Tennessee Health Science Center in Memphis, Tennessee, and was also affiliated with the Memphis Veterans Affairs Medical Center.
Dr. Deneve is currently a professor and surgical oncologist at the UNC School of Medicine and N.C. Basnight Cancer Hospital in Chapel Hill, North Carolina. He specializes in HIPEC, carcinomatosis, colorectal cancer, appendiceal cancer, and melanoma.
He also has experience treating rare cancers, like desmoplastic small round cell tumors and pseudomyxoma peritonei.
He joined UNC to provide complex surgical oncology care to patients diagnosed with challenging cancers and to help establish a Peritoneal Surface Malignancy program.[2] Establishing this program helps his team reach more patients with peritoneal mesothelioma.
Dr. Deneve takes great pleasure in working on a multidisciplinary team of physicians working to provide comprehensive treatment and enjoys the challenge and opportunity to help provide the best possible outcome for his patients.[2]
Research
Dr. Deneve is an active researcher who has co-authored and contributed to numerous publications and articles that have appeared in professional journals. These include:
Management of malignant bowel obstruction – Authors’ reply.Lancet Gastroenterol Hepatol. 2024 Jan;9(1):15. doi: 10.1016/S2468-1253(23)00367-9.PMID: 38070516 No abstract available.
ASO Visual Abstract: Malignant Solid Pseudopapillary Neoplasm of the Pancreas-An Orthogonal Analysis. Ann Surg Oncol. 2023 Nov 14. doi: 10.1245/s10434-023-14542-9. Online ahead of print.PMID: 37962743 No abstract available.
Malignant Solid Pseudopapillary Neoplasm of the Pancreas: An Orthogonal Analysis.
Ann Surg Oncol. 2024 Jan;31(1):475-487. doi: 10.1245/s10434-023-14343-0. Epub 2023 Sep 28.PMID: 37768414
Nationwide analysis of unplanned conversion during minimally invasive distal pancreatectomy for pancreatic adenocarcinoma. HPB (Oxford). 2023 Dec;25(12):1566-1572. doi: 10.1016/j.hpb.2023.08.009. Epub 2023 Aug 22.PMID: 37652810
Lymph node metastases in young patients with gastrointestinal stromal tumor: A nationwide analysis. J Surg Oncol. 2023 Dec;128(8):1268-1277. doi: 10.1002/jso.27431. Epub 2023 Aug 31.PMID: 37650827
Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial. Lancet Gastroenterol Hepatol. 2023 Oct;8(10):908-918. doi: 10.1016/S2468-1253(23)00191-7. Epub 2023 Aug 1.PMID: 37541263 Clinical Trial.
